Murray Stahl's BCYC Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 13,188 shares of Bicycle Therapeutics plc (BCYC) worth $61,192, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in BCYC, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 604 shares. Largest reduction occurred in Q4 2023, reducing 604 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Bicycle Therapeutics plc (BCYC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bicycle Therapeutics plc (BCYC) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -604 | Reduce 4.38% | 13,188 | $4.64 |
| Q4 2025 | -604 | Reduce 4.20% | 13,792 | $7.08 |
| Q3 2025 | +604 | Add 4.38% | 14,396 | $7.74 |
| Q2 2025 | -604 | Reduce 4.20% | 13,792 | $6.95 |
| Q4 2024 | +604 | Add 4.38% | 14,396 | $14.00 |
| Q3 2024 | -604 | Reduce 4.20% | 13,792 | $22.63 |
| Q4 2023 | -604 | Reduce 4.03% | 14,396 | $18.08 |
| Q1 2023 | +15,000 | New Buy | 15,000 | $21.27 |
Murray Stahl's Bicycle Therapeutics plc Investment FAQs
Murray Stahl first purchased Bicycle Therapeutics plc (BCYC) in Q1 2023, acquiring 15,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Bicycle Therapeutics plc (BCYC) for 13 quarters since Q1 2023.
Murray Stahl's largest addition to Bicycle Therapeutics plc (BCYC) was in Q1 2023, adding 15,000 shares worth $319,050.
According to the latest 13F filing for Q1 2026, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 13,188 shares of Bicycle Therapeutics plc (BCYC), valued at approximately $61,192.
As of the Q1 2026 filing, Bicycle Therapeutics plc (BCYC) represents approximately 0.00% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Bicycle Therapeutics plc (BCYC) was 15,000 shares, as reported at the end of Q1 2023.